The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $118.41

Today's change0.00 0.00%
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $118.41

Today's change0.00 0.00%
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc closed at (U.S.)$118.41.

Shares have lost 0.41% over the last five days, but sit 4.78% below their 52-week high. This security has outperformed the S&P 500 by 47.03% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $118.41
  • High--
  • Low--
  • Bid / Ask(U.S.) $116.00 / (U.S.) $121.20
  • YTD % change+59.37%
  • Volume0
  • Average volume (10-day)2,481,967
  • Average volume (1-month)1,747,825
  • Average volume (3-month)1,663,567
  • 52-week range(U.S.) $59.79 to (U.S.) $124.35
  • Beta0.32
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.21
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-94.84%

Vertex Pharmaceuticals Inc has a net profit margin of -94.84%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue179138118351
Total other revenue--------
Total revenue179138118351
Gross profit169129110338
Total cost of revenue1010913
Total operating expense321283335625
Selling / general / administrative75777475
Research & development191225239250
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)41-376278
Other operating expenses, total4879
Operating income-142-144-216-274
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-167-159-232-340
Income after tax-170-159-232-185
Income tax, total311-156
Net income-170-159-23244
Total adjustments to net income--------
Net income before extra. items-170-159-23244
Minority interest000229
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-170-159-23244
Inc. avail. to common incl. extra. items-170-159-23244
Diluted net income-170-159-23244
Dilution adjustment0000
Diluted weighted average shares236234233236
Diluted EPS excluding extraordinary itemsvalue per share-0.72-0.68-1.000.19
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.61-0.78-0.981.24